The lack of clarity surrounding the U.S.-China trade war is what's really hitting global growth, says ex- Deputy Treasury Secretary Sarah Bloom Raskin.World Economyread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
China's economy has long relied on factors such high levels of investments and an expanding labor force for growth. Those growth drivers are running out of steam.China Economyread more
India could benefit from the fallout in the U.S.-China trade war, experts told CNBC — but much-needed reforms on land and labor could prove to be a challenge for companies...Asia Economyread more
New crash tests show the Tesla Model 3 and the Audi e-tron, are among the safest models out on the road. The results bolster the theory electric vehicles may be better...Autosread more
U.S. consumers and growth in sectors such as technology have offset declines in other American industries, says Tom Finke, chairman and CEO of investment management firm...US Economyread more
The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle. While there, he's scheduled to meet with Boeing executives and be briefed...Airlinesread more
Last weekend's attacks on oil facilities — and the spike in crude prices that followed — should show that the world needs to stop relying on oil, says Helen Clark.Energyread more
The photo depicts Canadian leader Justin Trudeau wearing a turban and robe, with dark makeup on his hands, face and neck. Liberal Party spokesman confirms the photo is of...Electionsread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
The U.S. Federal Reserve on Wednesday cut its overnight rate by 25 basis points to a range of 1.75% to 2%, a move that was widely expected. The central bank, however, appeared...Asia Marketsread more
President Donald Trump said Thursday that the federal government will follow the example set by states and cities and begin suing drug companies and distributors for their role in the opioid epidemic.
"I keep saying, 'If the states are doing it, why isn't the federal government doing it?'" Trump said during a surprise appearance at the White House's opioid summit.
"So, that will happen," Trump said. "That will happen."
The president said he has already spoken to Attorney General Jeff Sessions about taking such federal action against the makers of prescription painkillers.
About 62,000 Americans died from drug overdoses in 2016, with most of those cases related to either prescription opioids, heroin and synthetic opioids such as fentanyl.
The negative economic effect of the opioid crisis recently was estimated to be more than $1 trillion from 2001 through last year, primarily from a loss in earnings and productivity from victims of fatal ODs.
Trump also said Thursday that the U.S. needs to get tough with drug dealers.
He said other countries which impose the death penalty for illegal drug selling have fewer problems with drug abuse than the U.S.
If the federal government actually does sue opioid manufacturers, it would be going significantly further than an action announced Tuesday.
Sessions that day revealed that the Justice Department would be filing a so-called statement of interest in hundreds of lawsuits that states and municipalities and Native American tribes already have pending against opioid makers.
The lawsuits, which claim that drugmakers, distributors and dispensers misled customers about the risks of addiction from opioids, have been consolidated in an action pending in U.S. District Court in Cleveland. The company defendants in the pending lawsuits have either publicly denied the allegations in statements to the media, or have declined to comment.
But "the statement of interest does not make the government party to the lawsuit," attorney Jesse Gessin told NBC News for a story published Thursday.
Gessin was one of several lawyers quoted by NBC who were skeptical that the Trump administration will get aggressive with drug companies over the issue.